newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

COAG
  • Hemab Therapeutics announced nine presentations at the ISTH 2026 Congress showcasing progress across its coagulation disorder pipeline.
  • New first-in-human data for HMB-002 validated proof of mechanism in Von Willebrand disease (VWD) by elevating VWF & FVIII levels via subcutaneous dosing, with multiple dose assessments currently underway.
  • A new program named HMB-003 was introduced as a potent, long-acting peptide plasmin inhibitor designed as a novel antifibrinolytic to reduce bleeding in multiple settings.
  • HMB-003 first-in-human studies are planned for the second half of 2026, with studies in heavy menstrual bleeding targeting 2027.
  • Long-term extension data for sutacimig demonstrated sustained reductions in annualized treated bleeding rates in Glanzmann thrombasthenia (GT).
  • Sutacimig has received FDA Breakthrough Therapy & EMA Priority Medicines (PRIME) designations, with Phase 3 initiation planned for the second half of 2026.
  • Preclinical data for sutacimig supports expansion into Factor VII deficiency (FVIID), where a Phase 2b study is in progress.
  • Real-world & natural-history analyses highlighted the high bleeding burden & significant psychological impact on patients living with Glanzmann thrombasthenia.
  • HMB-002 acts as a first-in-class subcutaneous prophylactic for VWD by shielding VWF from degradation to boost endogenous levels without compromising function.
  • HMB-003 demonstrated greater potency than tranexamic acid in inhibiting fibrinolysis in preclinical human whole-blood flow models.
  • Hemab emphasized its mission to address critical gaps in treating bleeding disorders with a pipeline designed to sustain life & human resilience.